In IMpower010, final DFS data revealed benefit with adjuvant atezolizumab versus BSC in patients with Stage II–IIIA NSCLC (AJCC-UICC 7th edition) and PD-L1 ≥1%, which appeared to be driven by a benefit in the PD-L1 ≥50% population (Table 1) (22, 25). The gene discussed is CD274; the disease is non-small cell lung carcinoma.